PERTH, Australia – Mesoblast Ltd. has signed a deal with China's Tasly Pharmaceutical Group that opens up the massive greater China market to the Aussie stem cell company to develop, manufacture and commercialize two of its late-stage allogeneic mesenchymal precursor cell (MPC) candidates for cardiovascular indications.
PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said.
PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said.
PERTH, Australia – Biotech and med-tech firms are booming in Australia and 87 percent of companies surveyed said they expect to grow this year, according to a survey conducted by AusBiotech.
PERTH, Australia – Sydney-based gene therapy company Benitec Biopharma Ltd. saw its stock more than double following a global out-licensing deal with Axovant Sciences Ltd. valued at $187.5 million for its DNA-directed RNA interference (ddRNAi) therapy BB-301.
PERTH, Australia – Sydney-based gene therapy company Benitec Biopharma Ltd. saw its stock more than double following a global out-licensing deal with Axovant Sciences Ltd. valued at $187.5 million for its DNA-directed RNA interference (ddRNAi) therapy BB-301.
PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease (GvHD).
PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease.
